Pierre Fabre Medicament

Alain Robert

Liliane Goetsch

Charlotte Beau-Larvor

Matthieu Broussas

Thierry Champion

Michel Perez

Jean-François Haeuw

Marie Lamothe

Ian Rilatt

Alexandra Jouhanneaud

Thien Ngoc Nguyen

Jean-Yves Bonnefoy

Laurent Chevalet

The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

IGF-1R antibody-drug-conjugate and its use for the treatment of cancer

The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.

IGF-1R antibody and its use as addressing vehicle for the treatment of cancer

The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.

Composition for the treatment of IGF-1R expressing cancer

The invention concerns a novel construct for expressing a gene coding for a recombinant protein of interest placed under the control of the Ptrp tryptophan operon promoter in a procaryotic host cell. The invention is characterised in that the construct comprises a nucleic sequence capable of inactivating the gene coding for a TnaA tryptophanase when said nucleic sequence is introduced in said host cell. The invention also concerns vectors containing said construct and host cells transformed by said vectors. The invention further concerns methods for producing said recombinant proteins using said novel constructs.

Constructs for controlled expression of recombinant proteins in prokaryotic cells

Growing community of inventors

Annemasse, France

Alain Robert